Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples